Abstract #3167

The IASLC/ ITMIG Thymic Epithelial Tumor Staging: Comparison of Staging Capability among Whole-Body PET/MRI, MRI including DWI, PET/CT and Conventional Radiological Examination

Yoshiharu Ohno^1,2, Yuji Kishida³, Sinichiro Seki^1,2, Kota Aoyagi⁴, Masao Yui⁴, Yoshimori Kassai⁵, Wakiko Tani⁶, Noriyuki Negi⁶, Katsusuke Kyotani⁶, and Takeshi Yoshikawa^1,2

¹Division of Functional and Diagnostic Imaging Research, Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Advanced Biomedical Imaging Research Center, Kobe University Graduate School of Medicine, Kobe, Japan, ³Division of Radiology, Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Center for Medical Research and Development, Toshiba Medical Systems Corporation, Otawara, Japan, ⁵MR Clinical Solution department, Toshiba Medical Systems Corporation, Otawara, Japan, ⁶Center for Radiology and Radiation Oncology, Kobe University Hospital, Kobe, Japan

Accurate stage assessment is essential for choosing the appropriate treatment strategy for thymic epithelial tumor patients. Recently, the International Association for the Study of Lung Cancer (IASLC) and International Thymic Malignancies Interest Group (ITMIG) proposed a new IASLC/ITMIG thymic epithelial tumor stage classification system. The purpose of this study was to compare the diagnostic capability for the IASLC/ ITMIG thymic epithelial tumor staging among whole-body FDG-PET/MRI, MRI, FDG-PET/CT and conventional radiological examinations based on guidelines.

This abstract and the presentation materials are available to members only; a login is required.

Join Here